Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Basilea Pharmaceutica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $46.00.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Basilea Pharmaceutica. This Buy consensus rating has held steady for over two years.
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include Cresemba, Zevtera, Derazantinib, BAL101553, and BAL3833. The company was founded on October 17, 2000 and is headquartered in Basel, Switzerland.